• Jade Biosciences released preclinical results on JADE301, an anti-IFN-β antibody candidate for dermatomyositis, ahead of clinical testing.
• Results were presented at the 2026 EADV Congress in an e-poster.
• Data showed strong target selectivity, robust pathway suppression, extended durability, and tolerability in animal studies, supporting infrequent subcutaneous dosing.
• A placebo-controlled Phase 1 single ascending-dose trial in 24 healthy volunteers is slated to start in Q4 2026.
• Interim Phase 1 data are expected in the second half of 2027, setting the next catalyst for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836570) on September 30, 2026, and is solely responsible for the information contained therein.